Dec 15, 2022 / 01:30PM GMT
Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications
Welcome, everyone, to Alnylam's R&D Day 2022. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications. We're pleased that you've tuned in to hear about progress across our portfolio. Turning to our agenda. You can see we have a very exciting lineup of presentations scheduled during our time together, starting with some strategic perspectives on how we are building our business and executing towards our R&D strategy to achieve our goals. We will then turn to deep dives on different elements of our pipeline spanning from our TTR franchise to progress with zilebesiran as a potential treatment for hypertension to our early and mid-stage pipeline before we close on perspective of what's percolating in the next wave of our R&D engine.
A few quick reminders before we dive in. This event is scheduled to run until 12:30 p.m., and we've incorporated a break into the agenda. We'll be hosting 2 live moderated Q&A sessions during the meeting. To
Alnylam Pharmaceuticals Inc R&D Day Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers